MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/evidoa2200239

Медицинская библиотека · NEJM evidence · 2023

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.

Long Georgina V, Stephen Hodi F, Lipson Evan J, Schadendorf Dirk, Ascierto Paolo A, Matamala Luis, Salman Pamela, Castillo Gutiérrez Erika, Rutkowski Piotr, Gogas Helen J, Lao Christopher D, Janoski De Menezes Juliana, Dalle Stéphane, Arance Ana, Grob Jean-Jacques, Keidel Sarah, Shaikh Anadil, Sobiesk Anne Marie, Dolfi Sonia, Tawbi Hussein A

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

A phase 2/3 trial — A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047) — evaluated nivolumab + relatlimab as a fixed-dose combination and found a significant progression-free survival (PFS) benefit over nivolumab monotherapy in previously untreated unresectable or metastatic melanoma. We now report updated PFS and safety data and the first results for overall survival (OS) and objective response rate (ORR).

METHODS

Patients were randomly assigned 1:1 to receive nivolumab 480 mg and relatlimab 160 mg fixed-dose combination or nivolumab 480 mg alone, given intravenously every 4 weeks. PFS (primary end point) according to the Response Evaluation Criteria in Solid Tumors, version 1.1, was assessed by blinded independent central review (BICR). Secondary end points, tested hierarchically, were OS and then ORR per Response Evaluation Criteria in Solid Tumors, version 1.1, per BICR.

RESULTS

At a median follow-up of 19.3 months, median PFS according to BICR was 10.2 months (95% confidence interval [CI], 6.5 to 14.8) with nivolumab + relatlimab versus 4.6 months (95% CI, 3.5 to 6.4) with nivolumab (hazard ratio, 0.78; 95% CI, 0.64 to 0.94). Median OS was not reached (NR) (95% CI, 34.2 to NR) with nivolumab + relatlimab versus 34.1 months (95% CI, 25.2 to NR) with nivolumab (hazard ratio, 0.80; 95% CI, 0.64 to 1.01; P=0.059) (prespecified value for statistical significance, P≤0.043). ORRs per BICR were 43.1% (95% CI, 37.9 to 48.4) versus 32.6% (95% CI, 27.8 to 37.7), respectively. Grade 3/4 treatment-related adverse events were observed in 21.1% of patients treated with nivolumab + relatlimab versus 11.1% treated with nivolumab.

CONCLUSIONS

The fixed-dose combination of nivolumab + relatlimab showed consistent PFS benefit versus nivolumab with approximately 6 months of additional median follow-up. The combination treatment did not reach the preplanned statistical threshold for OS, with a 10.3 percentage-point difference in ORR. Grade 3/4 treatment-related adverse events were more frequent with nivolumab + relatlimab versus nivolumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov number, NCT03470922.)

Для цитирования: Long Georgina V, Stephen Hodi F, Lipson Evan J, Schadendorf Dirk, Ascierto Paolo A, Matamala Luis, Salman Pamela, Castillo Gutiérrez Erika, Rutkowski Piotr, Gogas Helen J, Lao Christopher D, Janoski De Menezes Juliana, Dalle Stéphane, Arance Ana, Grob Jean-Jacques, Keidel Sarah, Shaikh Anadil, Sobiesk Anne Marie, Dolfi Sonia, Tawbi Hussein A. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.. NEJM evidence. 2023. DOI: 10.1056/evidoa2200239.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.